Hosted on MSN1d
The New Gold Rush in Rare Disease Treatments and Merck KGaA’s Acquisition of SpringWorks TherapeuticsFor many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...
GlobalData on MSN2d
New CEOs to join Merck KGaA’s executive boardJean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.
The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...
Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...
Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. | No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...
Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms ...
"Given Merck KGaA’s existing franchise in oncology, which constitutes about 25% of its healthcare sales in 2024, we see the potential acquisition of SpringWorks as likely complementary and ...
Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...
In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback